Literature DB >> 29627911

Pertussis and the Minnesota State Fair: Demonstrating a Novel Setting for Efficiently Conducting Seroepidemiologic Studies.

Erinn Sanstead1,2, Nicole E Basta3, Karen Martin4, Victor Cruz4, Kristen Ehresmann4, Shalini Kulasingam3.   

Abstract

Seroepidemiologic studies, which measure serum antibody levels produced in response to infection and/or vaccination, can be valuable tools for gaining insight into population level dynamics of infectious diseases. However, because seroepidemiologic studies are expensive and logistically challenging, they are not routinely conducted for surveillance purposes. We have identified a novel venue, state fairgrounds, in which annual sera samples from a population may be rapidly collected with minimal recruitment expenses. We conducted a pilot pertussis seroepidemiologic study over the course of 3 days at the 2016 Minnesota State Fair to determine if this setting, which hosts nearly 2 million visitors over 12 days each year, is viable for facilitating larger seroepidemiologic studies. A total of 104 adults and children were enrolled to provide a finger stick blood sample for serologic testing and to take a written survey regarding recent cough illness and pertussis vaccination. The survey was used to distinguish between antibodies induced by vaccination and pertussis infection. Elevated antibodies suggestive of recent infection were found among two adults. The prevalence of undetectable antibodies, suggestive of susceptibility, was 72.3% (95% CI 59.6, 85.1%) among 7-17 year olds, 53.8% (95% CI 26.7, 80.9%) among 1-6 year olds, and 23.3% (95% CI 8.2, 38.5%) among adults. Our ability to rapidly enroll participants and collect satisfactory specimens suggests that seroepidemiologic studies with 1000-2000 participants could efficiently be completed over the 12-day course of the Minnesota State Fair. This setting raises the possibility of efficiently conducting annual population-based seroepidemiologic studies to supplement traditional public health surveillance in estimating disease prevalence, monitoring vaccine impact, and identifying at-risk groups.

Entities:  

Keywords:  Infectious diseases; Pertussis; Serology; Vaccination

Mesh:

Substances:

Year:  2018        PMID: 29627911      PMCID: PMC6119492          DOI: 10.1007/s10900-018-0508-y

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  24 in total

1.  A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia.

Authors:  Heath Kelly; Michaela A Riddell; Heather F Gidding; Terry Nolan; Gwendolyn L Gilbert
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

2.  Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection.

Authors:  Sandra L Menzies; Vijay Kadwad; Lucia C Pawloski; Tsai-Lien Lin; Andrew L Baughman; Monte Martin; Maria Lucia C Tondella; Bruce D Meade
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

3.  Waning immunity to pertussis following 5 doses of DTaP.

Authors:  Sara Y Tartof; Melissa Lewis; Cynthia Kenyon; Karen White; Andrew Osborn; Juventila Liko; Elizabeth Zell; Stacey Martin; Nancy E Messonnier; Thomas A Clark; Tami H Skoff
Journal:  Pediatrics       Date:  2013-03-11       Impact factor: 7.124

Review 4.  Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries.

Authors:  Felicity T Cutts; Matt Hanson
Journal:  Trop Med Int Health       Date:  2016-07-01       Impact factor: 2.622

5.  Waning protection after fifth dose of acellular pertussis vaccine in children.

Authors:  Nicola P Klein; Joan Bartlett; Ali Rowhani-Rahbar; Bruce Fireman; Roger Baxter
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

6.  Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia.

Authors:  Piia Jõgi; Marje Oona; Karolin Toompere; Sirje Leedo; Jevgenia Epstein; Irja Lutsar
Journal:  Vaccine       Date:  2014-08-03       Impact factor: 3.641

7.  Frequency of unrecognized Bordetella pertussis infections in adults.

Authors:  J G Deville; J D Cherry; P D Christenson; E Pineda; C T Leach; T L Kuhls; S Viker
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

8.  Asymptomatic transmission and the resurgence of Bordetella pertussis.

Authors:  Benjamin M Althouse; Samuel V Scarpino
Journal:  BMC Med       Date:  2015-06-24       Impact factor: 8.775

9.  Under-recognized pertussis in adults from Asian countries: a cross-sectional seroprevalence study in Malaysia, Taiwan and Thailand.

Authors:  M T Koh; C-S Liu; C-H Chiu; W Boonsawat; V Watanaveeradej; N Abdullah; Xh Zhang; R Devadiga; J Chen
Journal:  Epidemiol Infect       Date:  2015-10-15       Impact factor: 2.451

10.  Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012.

Authors:  Lucy A McNamara; Tami Skoff; Amanda Faulkner; Lisa Miller; Kathy Kudish; Cynthia Kenyon; Marisa Bargsten; Shelley Zansky; Amy D Sullivan; Stacey Martin; Elizabeth Briere
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.